Based on the results of CALGB 80803, would you consider induction and/or concurrent FOLFOX in neoadjuvant treatment of esophageal adenocarcinoma?   

Great question. The CROSS regimen has been our standard for resectable GE junction and esophagus adenocarcinomas, but the data from the CALGB 80803 study are compelling.  For some patients with questionable disease resectability, usually due to extensive nodal involvement, we have been giving &...

I agree it is a great question, but I am sorry to say that I respectfully disagree with the answer. CALGB 80803 was a well-designed and well-conducted study that asked, and answered, a very specific question: If patients are not responding to the initially prescribed chemotherapy, is it better to co...

Thank you for the detailed and thoughtful answers. I do have few comments with all due respect to all experts commenting. As everyone knows, the CROSS regimen has great outcomes for ESCC and no one is debating it is the law of the land for that entity. Outcomes less impressive for adenocarcinom...

This is a great topic for discussion. I agree with both Dr. @Nina Sanford and Dr. @Harvey J. Mamon. Certainly, CALGB 80803 is an informative and thought-provoking trial demonstrating promising outcomes in the induction/concurrent FOLFOX setting and illustrating that switching from ineffective n...

I do think CALGB 80803 reignites the debate on the role of induction chemotherapy in patients with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinoma. We cannot ignore 2 important facts - 1. Most patients with initially non-metastatic eso/GEJ adenoca die of systemic disease. 2....